Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Other FDA-approved GLP-1 receptor agonists (liraglutide, semaglutide) share the same boxed warning regarding thyroid C-cell tumors as tirzepatide
Multiple randomized analyses show GLP-1sespecially semaglutideproduce meaningful hs-CRP reductions : STEP 1/2/3 (weight-management trials): Semaglutide 2.4 mg weekly reduced CRP by ~3944% vs
SURPASS-2: The head-to-head trial The SURPASS-2 trial is particularly relevant because it tested tirzepatide specifically in people already taking metformin (at least 1,500 mg daily)
and nearly a third (32%) achieved at least 25% weight reductions with tirzepatide compared to 16% with semaglutide
doi: 10.1007/s10545-005-8050-3
US$ 27.47
US$ 24.19
US$ 27.52
US$ 21.37
US$ 23.31
US$ 22.72
US$ 28.78
US$ 24.80
